Transaction · 0001676170-26-000026
MAZEMaze Therapeutics, Inc.
Coloma Jason V
Coloma Jason V, CEO, reported an open-market or private sale at Maze Therapeutics, Inc. involving 336.000000 shares for an estimated $10385.39. Reported holdings after the transaction were 12965.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Open-market sellSEC transaction code SCEO
- Trade date
- Nov 02, 2026
- Filing date
- Nov 04, 2026
How reported position traded is calculated
Shares sold ÷ (holdings after + shares sold). Estimated position before: 13,301 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
MAZE price since this filing
Daily closing prices, with the filing date and available return windowsMAZE · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -18.0%1w ago -3.7%1d ago -2.4%
Returns since7d30d90d180d1y
Transaction facts
Stored Form 4 columns with their raw values
- Type
- Sell Code S
- Identifier
- 0001676170-26-000026 Common Stock
- Transaction date
- Nov 02, 2026 Filed Nov 04, 2026, 09:13 PM · 2d delay
- Shares
- 336 sh $30.91 per share
- Estimated value
- -$10.3k Computed from shares × price
- Holdings after
- 12,965 sh Indirect · The Coloma 2021 Irrevocable Trust
Filing signal explanations
Badges describe filing facts only — not predictions.
Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling 10b5-1 Detected
Filing-only score
-6 points
Compact filing score computed from stored Form 4 facts. Version v1.
Mixed or weak signal
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Reported roles
Chief Executive Officer
Officer YesDirector Yes10% NoOther No
Footnotes & amended
- F1
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
- F2
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.805 to $30.795 per share, inclusive. The reporting person underta…
- F3
These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees.
- F4
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.805 to $31.70 per share, inclusive.
- F5
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.78 to $30.7175 per share, inclusive.
- F6
These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees.
- F7
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.795 to $31.70 per share, inclusive.
- F8
Reflects the transfer of 27,362 shares of Common Stock by the reporting person to the Coloma Family Trust on November 3, 2026.
Related transactions
Same SEC filing0 other transactions
Recent company activity
MAZE0 recent txs